Medicare AdvantagePrior AuthHigh impact
Pharmacy news roundup
BCBS Michigan·MI · Pharmacy, Oncology·Pharmacy
We identified it
Jul 23, 2026
Summary
This is a pharmacy news roundup from Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network (BCN) highlighting recent and upcoming pharmacy policy changes, including new step therapy requirements for Izervay (Medicare Advantage), prior authorization requirements for Boruzu and Ranluspec (commercial plans), and new medical oncology drug requirements. The practice must review specific alerts on the provider portal and implement corresponding billing and prior authorization workflows.
Action Required
REQUIREMENTS:
- Immediately: Billing and clinical teams must log into the Availity provider portal (availity.com) and navigate to BCBSM/BCN Payer Spaces > Resources > Secure Provider Resources > Alerts > Pharmacy to review all linked PDF alerts and identify specific drug names and requirements.
- Before Sept. 9, 2024: Implement prior authorization requirement for Boruzu for Blue Cross commercial URMBT members in billing system and pharmacy workflows.
- Before Oct. 1, 2024: Implement prior authorization and/or coverage requirements for additional medical oncology drugs for most BCBSM/BCN members in pharmacy system and EMR.
- Before June 15, 2024: Implement prior authorization requirement for Ranluspec for most BCBSM commercial members in pharmacy system.
- Ongoing: Subscribe to Provider Alerts Weekly (link provided in policy) to receive automated weekly email notifications of future pharmacy policy changes and new effective dates.
- Assign staff member to review Availity portal monthly for new pharmacy alerts to ensure compliance with all BCBSM/BCN requirements.
- Update pharmacy team protocols and encounter forms to reflect prior authorization and step therapy requirements for affected medications.
- Failure to implement prior authorizations will result in claim denials and treatment delays for members.